SF3B1 and myelodysplastic syndrome: The observation that SF3B1 mutations with a lower VAF had no significant impact on response to lenalidomide may be explained by the fact that SF3B1 is frequently affected in clonal hematopoiesis of indeterminate potential, a condition increasingly occurring in elderly people with mutations at diverse VAFs [34] The observation of non-responsiveness to lenalidomide in SF3B1-mutant del(5q) MDS is of clinical importance.